Reistone announces presentation at the 40th Annual J.P. Morgan Healthcare conference in January 2022


Shanghai, China, and Chicago, USA, December 23, 2021 - Reistone Biopharma (“Reistone”), a global biotechnology company focused on development of treatments for immune and inflammation related diseases, announced that Dr. Min Irwin, CEO & Co-Founder, will give a corporate presentation at 10:00 AM Eastern time on Tuesday, January 11, 2022, at the 40th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, January 10-23, 2022.  J.P. Morgan is one of the largest and most informative healthcare conferences globally, bringing together big pharma and emerging fast-growth companies, innovative leaders, and members of the investment community. We are honored to have the opportunity to present at the conference to share the progress of our many programs. 

A live audio webcast can be found at

Reistone was founded in January 2018 and is headquartered in Shanghai, China with additional operations in Beijing, China, and Chicago and Boston, United States.  Currently, Reistone has two ongoing phase 3 programs as well as six active phase 2 programs for multiple assets.  In addition, it has two ongoing phase 1 programs for two innovative compounds. On January 21, 2021, SHR0302 (Reistone’s highly selective JAK1 inhibitor) received breakthrough therapy designation from China’s CDE, indicated for moderate-to-severe atopic dermatitis patients aged 12 and above.  Moreover, Reistone has launched its own discovery laboratory for small and large molecules and currently has multiple pipeline compounds.  

Reistone’s current programs cover the following conditions:  immune related dermatological diseases, inflammatory bowel diseases (IBD), and other autoimmune related conditions in CNS and kidney.  Further information about the company and its drug development programs and capabilities may be found online at . 

Date of issue:2021-12-24
Share to:
Learn more